"The EDSS has a number of limitations and may also measure changes that are not related to MS, such as older age and multiple ...

Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist ...

When he was 25, he learned that he had multiple sclerosis. He coped with the disease throughout a long career at several ...

After getting through a significant difficulty, many of us reject being described in favorable terms. Why don't we want to ...

Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in ...

A team of doctors in Mumbai treated a 24-year-old engineering student who was suffering from multiple sclerosis, a chronic disease that affects the nervous system. For the patient, Sushant Chavan, ...

Cohen also twice survived colon cancer, a blood clot in his lung and, in his later years, was left legally legally blind by the MS, according to People.

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

"I tell my right foot to go somewhere, and it wants to go somewhere else. I gotta be very precise about, moving around, especially when I start moving fast on stage." ...

Nov. 18, 2024 — Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...